These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 20100757)

  • 1. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatrics; 2010 Feb; 125(2):e208-13. PubMed ID: 20100757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.
    Boom JA; Tate JE; Sahni LC; Rench MA; Hull JJ; Gentsch JR; Patel MM; Baker CJ; Parashar UD
    Pediatrics; 2010 Feb; 125(2):e199-207. PubMed ID: 20083525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice.
    Bégué RE; Perrin K
    Pediatrics; 2010 Jul; 126(1):e40-5. PubMed ID: 20587671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia.
    Field EJ; Vally H; Grimwood K; Lambert SB
    Pediatrics; 2010 Sep; 126(3):e506-12. PubMed ID: 20732946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotavirus live, oral, pentavalent vaccine.
    Tom-Revzon C
    Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).
    Vesikari T; Itzler R; Matson DO; Santosham M; Christie CD; Coia M; Cook JR; Koch G; Heaton P
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S29-35. PubMed ID: 18162243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
    Leshem E; Givon-Lavi N; Tate JE; Greenberg D; Parashar UD; Dagan R
    Clin Infect Dis; 2016 May; 62 Suppl 2():S155-60. PubMed ID: 27059350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua.
    Mast TC; Khawaja S; Espinoza F; Paniagua M; Del Carmen LP; Cardellino A; Sánchez E
    Pediatr Infect Dis J; 2011 Nov; 30(11):e209-15. PubMed ID: 21768920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States.
    Mast TC; Wang FT; Su S; Seeger JD
    Pediatr Infect Dis J; 2015 Jun; 34(6):615-20. PubMed ID: 25831421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases.
    Cortese MM; Tate JE; Simonsen L; Edelman L; Parashar UD
    Pediatr Infect Dis J; 2010 Jun; 29(6):489-94. PubMed ID: 20354464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States.
    Payne DC; Staat MA; Edwards KM; Szilagyi PG; Gentsch JR; Stockman LJ; Curns AT; Griffin M; Weinberg GA; Hall CB; Fairbrother G; Alexander J; Parashar UD
    Pediatrics; 2008 Dec; 122(6):1235-43. PubMed ID: 19047240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of vaccination with the pentavalent rotavirus vaccine in Nicaragua as determined using the screening method.
    Cardellino A; Khawaja S; Sánchez Cruz E; Mast TC
    Hum Vaccin Immunother; 2013 Jul; 9(7):1449-53. PubMed ID: 23571175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule.
    Buttery JP; Lambert SB; Grimwood K; Nissen MD; Field EJ; Macartney KK; Akikusa JD; Kelly JJ; Kirkwood CD
    Pediatr Infect Dis J; 2011 Jan; 30(1 Suppl):S25-9. PubMed ID: 21183837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Ciarlet M; Schödel F
    Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
    Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.
    Vesikari T; Karvonen A; Ferrante SA; Kuter BJ; Ciarlet M
    Pediatr Infect Dis J; 2010 Oct; 29(10):957-63. PubMed ID: 20442684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.